PARP Inhibitor Drugs

PARP inhibitor drugs are targeted cancer medicines taken by mouth in many treatment plans. PARP enzymes help cells detect and repair certain types of DNA damage. Blocking these enzymes places extra stress on cancer cells that already have difficulty repairing DNA through another pathway.

Medicines in this group include olaparib, niraparib, rucaparib, and talazoparib. They are not interchangeable: approval, formulation, interactions, and monitoring differ. A cancer team chooses a medicine after considering the cancer type, biomarker results, previous treatment, blood counts, kidney function, liver function, and other medicines.

When PARP activity is blocked, some damaged DNA remains unrepaired. Cancer cells with an underlying weakness in a separate repair pathway may accumulate damage and stop dividing or die. This selective pressure is why tumour testing can matter. A biomarker result may support use, but it does not predict the same response for every person.

PARP inhibitors are used for selected ovarian, breast, pancreatic, prostate, and other cancers, depending on the medicine and local treatment guidance. They may be used after an earlier treatment, as maintenance when disease has responded, or for cancer that has returned or spread. The team explains the purpose and how response will be assessed.

Alternatives can include surgery, chemotherapy, hormone treatment, immunotherapy, another targeted medicine, radiotherapy, or supportive care. The appropriate option depends on tumour biology, previous medicines, symptoms, organ function, and treatment goals. Some people receive a PARP inhibitor alongside other care; others need a different strategy if the cancer lacks the relevant repair weakness or if side effects become difficult.

Take the medicine at the prescribed times and follow instructions about missed doses. Swallow tablets as directed and check before starting any new prescription, over-the-counter medicine, or supplement. Keep appointments for blood tests because changes in blood counts may develop before symptoms are obvious.

Fatigue, nausea, reduced appetite, diarrhoea or constipation, headache, and low blood counts can occur. Tell the team about breathlessness, chest discomfort, fever, unusual bruising, persistent infection symptoms, or marked weakness. Pregnancy planning, breastfeeding, and contraception should be discussed because treatment may harm a developing pregnancy.

PARP inhibitor drugs block DNA-repair enzymes, which can make selected cancer cells unable to recover from DNA damage.

Treatment continues while it is helping and side effects remain manageable, according to the prescribed plan. Dose interruptions or reductions can be used when needed; do not make these changes alone. Follow-up may include symptom review, blood tests, scans, and checks for interactions with other medicines.